Results The mean value of IL-13Rα2 was significantly higher in delayed BA group
(11.05±10.9 ng/ml) compared to early BA (0.34±0.37 ng/ml), non-BA (0.54±0.85 ng/ml) and …

Background Biliary atresia (BA) is a paediatric cholestatic disease characterized by a
progressive fibro‐inflammation of the biliary tree. Current treatment of choice is to establish …

Biliary atresia (BA) is a neonatal obliterative cholangiopathy of unknown etiology. Despite
the Kasai procedure, hepatic fibrosis and portal hypertension (PH) still occur. Interleukin-8 …

The standard‐of‐care treatment for biliary atresia (BA) is surgical restoration of bile flow by
Kasai portoenterostomy. We aimed to study serum interleukin‐(IL‐) 12p40, a natural …

Background Biliary atresia (BA) is a severe congenital disorder with progressive obstructive
cholangiopathy in young children. The inflammatory process has been recognized as one of …

Background & Aims Biliary atresia (BA) is a rare disease in infants, with unknown
mechanisms of pathogenesis. It is characterized by hepatobiliary inflammatory, progressive …

Purpose: The aim of this study was to determine whether chemokines such as serum IP-10
levels in patients with biliary atresia (BA) correlate with liver function and histology and …

in a recent issue of Gastroenterology. They investigated the role of interleukin 17A produced
by γδ T cells in the pathogenesis of biliary atresia (BA) in a mouse model and in infants with …

Objectives: The present study aimed to estimate the value of serum interleukin-33 (IL-33)
levels in infants with cholestasis, correlate serum IL-33 levels with the clinicopathological …

Background/Aims: Biliary Atresia (BA) is a devastating pediatric liver disease and
characterized by aggressive liver fibrosis progression. The Interleukin-33 (IL-33)/ST2 …